Enanta Pharmaceuticals, Inc. - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026 (Fiscal Q2 2026). Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs for virology and immunology. The company generates revenue primarily through royalties from its collaboration with AbbVie regarding the HCV treatment MAVYRET/MAVIRET. As of March 31, 2026, the company had 29,078,380 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2026 | Six Months Ended Mar 31, 2026 | Balance Sheet (Mar 31, 2026) |
|---|---|---|---|
| Total Revenue | $17,159 | $35,774 | - |
| Net Loss | $(13,091) | $(25,029) | - |
| Loss Per Share (Basic/Diluted) | $(0.45) | $(0.87) | - |
| Operating Expenses | $29,011 | $58,879 | - |
| Cash & Cash Equivalents | - | - | $34,928 |
| Marketable Securities (Short & Long Term) | - | - | $192,084 |
| Total Liquidity | - | - | $227,012 |
| Liability: Sale of Future Royalties | - | - | $128,770 |
Material Changes vs. Prior Period
- Revenue Growth: Royalty revenue increased 15% year-over-year (YoY) for the quarter ($17.2M vs. $14.9M) and 12% for the six-month period ($35.8M vs. $31.9M), driven by higher reported HCV sales by AbbVie.
- Expense Reduction: Total operating expenses decreased significantly. R&D expenses dropped 31% YoY for the quarter ($19.4M vs. $28.1M) and 28% for the six-month period ($40.3M vs. $55.7M). This was primarily due to the timing of clinical trials in the RSV program.
- Net Loss Improvement: Net loss narrowed to $13.1M for the quarter from $22.6M in the prior year period, and to $25.0M for the six months from $44.9M.
- Financing Activity: The company completed a public offering in October 2025, raising net proceeds of approximately $69.9M, which significantly bolstered cash reserves compared to the prior year.
- Interest Expense: Interest expense increased to $3.3M for the quarter (from $1.7M) due to higher royalty payments to OMERS under the royalty sale agreement.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($227.0M) combined with retained royalty cash flows will fund operations into fiscal 2029.
- Program Updates:
- RSV: Positive Phase 2b results announced for zelicapavir in high-risk adults (Sept 2025) and pediatric patients (Dec 2024). Pivotal study design updates expected in Q2 2026.
- Immunology: First participant dosed in Phase 1 trial for KIT inhibitor EDP-978 (April 2026). IND filing for STAT6 inhibitor EPS-3903 expected in H2 2026.
- Legal Contingencies: The company is appealing a District Court summary judgment ruling that invalidated its '953 Patent regarding Pfizer's Paxlovid. An oral argument occurred in May 2026, with a Federal Circuit decision expected by September 2026. A separate infringement action is pending in the European Unified Patent Court.
- Risks: Continued operating losses, dependence on AbbVie royalties, uncertainty of clinical trial outcomes, and potential inability to secure future financing.
Investor Verification Checklist
- Royalty Dependency: Verify the sustainability of AbbVie's MAVYRET sales and the impact of the 54.5% royalty share sold to OMERS on future cash flows.
- RSV Clinical Path: Confirm the timeline and design of the pivotal zelicapavir study, as this is the primary near-term value driver.
- Legal Outcome: Monitor the Federal Circuit appeal decision regarding the Pfizer patent litigation, which could impact future revenue or incur significant costs.
- Burn Rate: Assess the trajectory of R&D spending as the company transitions from early-stage discovery to pivotal trials in RSV and immunology.
- Capital Structure: Review the terms of the Series 1 nonconvertible preferred stock liability ($1.3M) and the amortization schedule of the OMERS royalty liability.